Ranibizumab

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Ranibizumab is an anti-VEGF monoclonal antibody fragment originally used for neovascular (wet) age-related macular degeneration and related retinal vascular diseases. The TxGNN model predicts it may be effective for Severe Nonproliferative Diabetic Retinopathy, with 6 clinical trials (including 3 completed Phase 3 RCTs) and 19 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not specified in this evidence pack (`original_indications` empty, `original_moa` = Data Gap). Publicly known original indication: neovascular AMD and related retinal vascular disease
Predicted New Indication	Severe Nonproliferative Diabetic Retinopathy
TxGNN Prediction Score	99.99%
Evidence Level	L1
Finland Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for this candidate is not available in the evidence pack (DG002, High severity). Based on known pharmacology, ranibizumab is part of the anti-VEGF (vascular endothelial growth factor inhibitor) class of biologics — a humanized monoclonal antibody Fab fragment that binds and neutralizes VEGF-A. Its efficacy in neovascular retinal disease is well established, and mechanistically it is directly applicable to diabetic retinopathy.

Diabetic retinopathy and the diseases ranibizumab was originally developed for (wet AMD, diabetic macular edema) share a common pathophysiological driver: pathological VEGF-mediated neovascularization and vascular permeability in the retina. Progression to severe nonproliferative and proliferative diabetic retinopathy is closely tied to rising intraocular VEGF levels, which is exactly the target ranibizumab neutralizes.

Notably, the clinical trial and literature evidence retrieved for this candidate is unusually extensive for a "predicted" indication — including multiple completed Phase 3 RCTs and a 2025 JAMA Ophthalmology trial (Pavilion). This suggests TxGNN is here reproducing a mechanistically sound and largely clinically validated relationship rather than a purely novel hypothesis, which strengthens confidence in the prediction even though formal MOA/indication fields are missing from this evidence pack.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00444600	Phase 3	Completed	691	Compared laser alone, laser + triamcinolone, laser + ranibizumab, and ranibizumab alone for diabetic macular edema
NCT04503551	Phase 3	Completed	174	Port Delivery System with ranibizumab vs comparator in diabetic retinopathy without center-involved DME
NCT02634333	Phase 3	Completed	399	Intravitreal anti-VEGF for prevention of vision-threatening DR in high-risk eyes
NCT03452657	Phase 3	Unknown	118	Intravitreous ranibizumab vs sham injection for prevention of high-risk DR
NCT02834663	Phase 4	Completed	25	Intravitreal ranibizumab for macular edema with NPDR; effects on microaneurysm turnover and non-perfused retinal area
NCT05222633	N/A	Unknown	1000	Real-world observational study of anti-VEGF therapy (ranibizumab, aflibercept, conbercept) in AMD, PDR, macular edema, and CNV

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40048178	2025	RCT	JAMA Ophthalmology	Pavilion trial: Port Delivery System with ranibizumab vs monitoring in NPDR without macular edema
36774994	2023	Meta-Analysis	Ophthalmology Retina	Baseline DR severity and time to DME resolution with ranibizumab across Phase 3 trials
39673354	2024	Systematic Review	Health Technology Assessment	Anti-VEGF drugs vs laser photocoagulation for diabetic retinopathy
40347224	2025	Systematic Review	Health Technology Assessment	Anti-VEGF vs laser photocoagulation for DR — systematic review and economic analysis
32606578	2020	Post-hoc Analysis	Clinical Ophthalmology	Predictors of early DR regression with ranibizumab in RIDE/RISE trials
30973596	2019	Observational Study	JAMA Ophthalmology	Retinal nonperfusion characteristics in severe NPDR and PDR on ultra-widefield angiography
33966556	2021	Review	Expert Opinion on Biological Therapy	Overview of ranibizumab for the treatment of diabetic retinopathy
31669065	2019	Review	Journal of Diabetes and its Complications	Advances in the treatment of diabetic retinopathy; VEGF-A as key driver of progression
37278412	2023	Modeling Study	BMJ Open Ophthalmology	Simulation of long-term impact of intravitreal anti-VEGF therapy on severe NPDR
40466685	2025	Clinical Observational Study	Georgian Medical News	Anti-VEGF combined with panretinal photocoagulation in diabetic retinopathy

Finland Market Information

Ranibizumab is currently not marketed in Finland per this evidence pack (market_status: 未上市, total_licenses: 0). No authorization records are available.

Safety Considerations

Please refer to the package insert for safety information.

Note: this evidence pack flags a Blocking-severity data gap (DG001) — the TFDA/product-label warnings and contraindications could not be retrieved, which per the internal pipeline definition prevents entry into the S1 safety initial assessment. Drug interaction data query also returned no results (not_found).

Conclusion and Next Steps

Decision: Hold

Rationale:

Efficacy evidence is strong (L1: 3 completed Phase 3 RCTs plus extensive supporting literature), and the VEGF-driven mechanistic link between the original indication and severe NPDR is sound.
However, a Blocking-severity data gap (DG001: missing TFDA package insert / warnings / contraindications) prevents completion of the initial safety assessment, and the drug is not currently marketed in Finland (0 authorizations).

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) — required to clear the S1 safety gate (DG001)
Formal mechanism of action documentation from DrugBank (DG002)
Drug interaction (DDI) data, as the current query returned no results
Regulatory pathway assessment for Finland market entry, given zero existing local authorizations
Formal classification (study type / tier / relevance) of the currently "pending" clinical trial and literature records
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.